
<!DOCTYPE html>
<html>
<head>
    <meta charset="utf-8"><meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=0">
    <title>GI Intelligence Terminal</title><script src="https://cdn.jsdelivr.net/npm/chart.js"></script>
    <style>
        :root { --primary: #3498db; --success: #2ecc71; --warning: #ffb300; --bg: #f5f7fa; --text: #2c3e50; }
        body { font-family: -apple-system, sans-serif; background: var(--bg); color: var(--text); margin: 0; padding: 8px; }
        .card { background: #fff; border-radius: 12px; padding: 12px; box-shadow: 0 2px 8px rgba(0,0,0,0.05); margin-bottom: 12px; border: 1px solid #e0e0e0; }
        
        /* ğŸ© ë„í‘œ ì¤‘ì•™ ë°°ì¹˜ ìŠ¤íƒ€ì¼ */
        .chart-container { background: #fff; border-radius: 12px; padding: 12px; border: 1px solid #e0e0e0; height: 160px; display: flex; justify-content: center; margin-bottom: 12px; }
        
        .paper-item { margin-bottom: 8px; border-radius: 10px; overflow: hidden; list-style: none; border: 1px solid #eee; }
        summary { padding: 12px; cursor: pointer; outline: none; list-style: none; }
        summary::-webkit-details-marker { display: none; }
        .meta { font-size: 0.7rem; color: #7f8c8d; margin-bottom: 4px; display: flex; align-items: center; gap: 4px; flex-wrap: wrap; }
        .title-row { font-weight: bold; font-size: 0.9rem; line-height: 1.4; display: flex; align-items: flex-start; }
        .arrow-icon { display: inline-block; transition: transform 0.2s; color: var(--primary); margin-right: 6px; flex-shrink: 0; }
        details[open] .arrow-icon { transform: rotate(90deg); }
        .badge { padding: 1px 4px; border-radius: 3px; font-size: 0.6rem; font-weight: bold; color: #fff; }
        .rct { background: #e74c3c; } .gl { background: var(--success); } .if { background: #8e44ad; }
        .content { padding: 12px; background: #f9f9f9; border-top: 1px solid #eee; font-size: 0.85rem; }
        .clinical-note { background: #fff8e1; border-left: 3px solid var(--warning); padding: 10px; border-radius: 6px; margin-bottom: 10px; font-size: 0.8rem; color: #5d4037; }
        .btm-box { background: #ebf5ff; padding: 10px; border-radius: 6px; margin-bottom: 10px; border-left: 3px solid var(--primary); font-weight: bold; }
        .btn { flex: 1; padding: 8px; border-radius: 6px; text-align: center; text-decoration: none; font-weight: bold; cursor: pointer; font-size: 0.8rem; border: none; color: #fff; }
        .pub { background: var(--primary); } .shr { background: var(--success); }
        h3 { font-size: 1.1rem; margin: 15px 0 10px 0; border-bottom: 2px solid #eee; padding-bottom: 5px; }
    </style>
</head>
<body>
    <div class="card" style="text-align:center;">
        <h1 style="margin:0; font-size:1.4rem;">ğŸ¥ GI Intel Terminal</h1>
        <small style="font-size:0.75rem;">Updated: 2026-02-28 13:36 KST</small>
    </div>
    
    <div class="card" style="border-top: 5px solid #e74c3c;">
        <h2 style="margin-top:0; font-size:1rem; color:#e74c3c;">ğŸ”¥ Weekly Top 3 (Practice-Changing)</h2>
        
    <details class="paper-item" style="border-left:5px solid #e74c3c;background:#fffafa;">
        <summary>
            <div class="meta"><span class='badge if'>IF 29.4</span> <b>European journal of gastroenterology & hepatology</b>  ğŸ”¥</div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>The multifaceted role of secretome in hepatocellular carcinoma: a systematic review and meta-analysis.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ HCC surveillance ì¬ì„¤ì •</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>The secretome shows promise as a diagnostic and prognostic tool in HCC, with high sensitivity and specificity. However, further large-scale, standardized studies are needed to validate these findings and facilitate clinical translation.</div>
            <div class="abs">Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality, with a poor prognosis due to late diagnosis and limited treatment options. The secretome, encompassing proteins, metabolites, and extracellular vesicles secreted by cells, has emerged as a promising tool for early detection, risk stratification, and therapeutic targeting in HCC. Recent studies suggest that secretome-derived biomarkers improve diagnostic accuracy and predict survival outcomes. However, variability in methodologies and findings necessitates a comprehensive synthesis of evidence.<br><br>A systematic review and meta-analysis were conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. PubMed, EMBASE, and Scopus databases were searched on 2 May 2025 for studies evaluating the diagnostic and prognostic value of the secretome in HCC. Eligibility criteria included original research reporting sensitivity, specificity, or survival outcomes. Risk of bias was assessed using Quality Assessment of Diagnostic Accuracy Studies-2. Pooled estimates of sensitivity, specificity, and hazard ratios (HRs) were calculated using random-effects models, with heterogeneity assessed via IÂ² statistics.<br><br>Five studies met the inclusion criteria. The secretome demonstrated high diagnostic accuracy, with a pooled sensitivity of 95.9% [95% confidence intervals (CI): 40-100] and specificity of 89.6% (95% CI: 43.1-99). Moderate heterogeneity (IÂ² = 44%) was observed. For survival outcomes, the pooled HR was 2.37 (95% CI: 0.87-6.41), though statistical significance was not reached (Pâ€…=â€…0.07).<br><br>The secretome shows promise as a diagnostic and prognostic tool in HCC, with high sensitivity and specificity. However, further large-scale, standardized studies are needed to validate these findings and facilitate clinical translation.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41757612/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41757612')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41757612" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ The multifaceted role of secretome in hepatocellular carcinoma: a systematic review and meta-analysis.\nğŸ¥ European journal of gastroenterology & hepatology\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41757612/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:5px solid #e74c3c;background:#fffafa;">
        <summary>
            <div class="meta"> <b>Frontiers in genetics</b>  ğŸ”¥</div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>The impact of circulating tumor DNA on the prognosis of liver cancer and its predictive value: a meta analysis.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ HCC surveillance ì¬ì„¤ì •</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>ctDNA is associated with adverse prognosis in HCC and may offer moderate predictive accuracy for recurrence. Standardized protocols for sampling and analysis are required to facilitate broader clinical translation.</div>
            <div class="abs">ctDNA is a promising biomarker in oncology. However, its prognostic and predictive value in HCC remains underexplored. This meta-analysis aims to evaluate the prognostic impact of ctDNA in HCC and its predictive value for recurrence.<br><br>A systematic review and meta-analysis were performed following PRISMA guidelines. PubMed, Embase, Web of Science, and CNKI were searched up to 1 June 2025, for studies assessing ctDNA in HCC patients with reported survival outcomes or predictive accuracy. Studies reporting hazard ratios for overall or disease-free survival, or AUCs for prediction, were included. Two reviewers independently screened studies and assessed quality using the Newcastle-Ottawa Scale (NOS). Meta-analyses used random- or fixed-effects models depending on heterogeneity, with sensitivity analyses performed to assess robustness.<br><br>A total of 219 records were screened from PubMed, Embase, Web of Science, and CNKI, and 8 studies comprising 1,907 patients were included. ctDNA positivity was significantly associated with poorer OS, with a pooled HR of 2.34 (95% CI 1.96-2.78; p < 0.0001). Moderate heterogeneity was observed (I<br><br>ctDNA is associated with adverse prognosis in HCC and may offer moderate predictive accuracy for recurrence. Standardized protocols for sampling and analysis are required to facilitate broader clinical translation.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41757268/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41757268')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41757268" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ The impact of circulating tumor DNA on the prognosis of liver cancer and its predictive value: a meta analysis.\nğŸ¥ Frontiers in genetics\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41757268/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:5px solid #e74c3c;background:#fffafa;">
        <summary>
            <div class="meta"> <b>The American journal of managed care</b>  ğŸ”¥</div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Quality of life: the pending outcome in idiopathic pulmonary fibrosis.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>Recent real-world evidence on idiopathic pulmonary fibrosis (IPF) has provided important insights into survival and disease progression; however, critical patient-centered outcomes remain insufficiently addressed. The articleÂ "Real-World Data on the Course of Idiopathic Pulmonary Fibrosis," published in an October 2024 supplement to The American Journal of Managed Care , highlights this limitation by focusing predominantly on objective clinical parameters while lacking systematic evaluation of health-related quality of life (HRQOL). This gap is particularly relevant given limited evidence on how antifibrotic therapies affect symptoms, pulmonary function, and psychosocial well-being beyond radiologic progression. QOL is especially relevant in resource-limited settings, where demonstrating benefits in symptom control and functional status may influence therapeutic decisions, coverage policies, and resource allocation. Although international clinical practice guidelines, including those of the American Thoracic Society and the European Respiratory Society, recognize QOL as a key domain in IPF management, they also acknowledge the paucity of evidence addressing psychosocial and functional outcomes. Notably, major clinical trials such as INPULSIS and ASCEND, while demonstrating efficacy in slowing forced vital capacity decline, did not incorporate HRQOL as a primary outcome. Recent guideline updates propose a conceptual framework integrating validated measures of symptoms, pulmonary function, and psychosocial impact. However, these dimensions have not yet been systematically embedded in clinical research. Reanalysis of existing data and future studies using this framework are warranted. AÂ comprehensive evaluation of quality of life is therefore a clinical and ethical imperative for advancing patient-centered and holistic care in IPF.</div>
            <div class="abs">Recent real-world evidence on idiopathic pulmonary fibrosis (IPF) has provided important insights into survival and disease progression; however, critical patient-centered outcomes remain insufficiently addressed. The articleÂ "Real-World Data on the Course of Idiopathic Pulmonary Fibrosis," published in an October 2024 supplement to The American Journal of Managed Care , highlights this limitation by focusing predominantly on objective clinical parameters while lacking systematic evaluation of health-related quality of life (HRQOL). This gap is particularly relevant given limited evidence on how antifibrotic therapies affect symptoms, pulmonary function, and psychosocial well-being beyond radiologic progression. QOL is especially relevant in resource-limited settings, where demonstrating benefits in symptom control and functional status may influence therapeutic decisions, coverage policies, and resource allocation. Although international clinical practice guidelines, including those of the American Thoracic Society and the European Respiratory Society, recognize QOL as a key domain in IPF management, they also acknowledge the paucity of evidence addressing psychosocial and functional outcomes. Notably, major clinical trials such as INPULSIS and ASCEND, while demonstrating efficacy in slowing forced vital capacity decline, did not incorporate HRQOL as a primary outcome. Recent guideline updates propose a conceptual framework integrating validated measures of symptoms, pulmonary function, and psychosocial impact. However, these dimensions have not yet been systematically embedded in clinical research. Reanalysis of existing data and future studies using this framework are warranted. AÂ comprehensive evaluation of quality of life is therefore a clinical and ethical imperative for advancing patient-centered and holistic care in IPF.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41759200/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41759200')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41759200" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Quality of life: the pending outcome in idiopathic pulmonary fibrosis.\nğŸ¥ The American journal of managed care\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41759200/</textarea>
        </div>
    </details>
    </div>

    <div class="chart-container">
        <canvas id="c2"></canvas>
    </div>

    <div class="card">
        <button id="fBtn" onclick="toggleF()" style="width:100%; padding:10px; border-radius:20px; border:1px solid var(--success); background:#fff; color:var(--success); font-weight:bold; cursor:pointer; font-size: 0.85rem;">ğŸ“‹ ê°€ì´ë“œë¼ì¸ë§Œ ë³´ê¸°</button>
        <div class='sec-group'><h3>ğŸ GI Track</h3>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Medicina (Kaunas, Lithuania)</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>From Inflammation to Thrombosis: The Prothrombotic State and Cardiovascular Risk in Inflammatory Bowel Disease.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>Inflammatory bowel disease (IBD) is associated with an increased risk of venous thromboembolic events (VTEs) and a moderate risk of arterial cardiovascular events. This varies with inflammatory activity and acute-care exposure, with pathophysiological data supporting a thromboinflammatory phenotype in which intestinal inflammation influences systemic vascular homeostasis through innate immune activation, coagulation-platelet crosstalk, endothelial dysfunction, impaired fibrinolysis, and immunothrombosis. Clinically, prevention and management should be integrated into routine care and anchored in sustained, steroid-sparing disease control, combined with guideline-based in-hospital thromboprophylaxis and standard cardiovascular prevention. Decisions regarding anticoagulant therapy after VTEs should follow established principles while recognizing that recurrence prevention depends not only on anticoagulant choice but also on minimizing repeated inflammatory and treatment-related risk exposures. Cardiovascular risk assessment and optimization of modifiable factors should be considered before therapy escalation or treatment switching. Future advances will likely come from more personalized risk assessment across dynamic high-risk windows and from adjunctive, mechanism-informed strategies targeting key nodes of the gut-vascular interface and immunothrombosis.</div>
            <div class="abs">Inflammatory bowel disease (IBD) is associated with an increased risk of venous thromboembolic events (VTEs) and a moderate risk of arterial cardiovascular events. This varies with inflammatory activity and acute-care exposure, with pathophysiological data supporting a thromboinflammatory phenotype in which intestinal inflammation influences systemic vascular homeostasis through innate immune activation, coagulation-platelet crosstalk, endothelial dysfunction, impaired fibrinolysis, and immunothrombosis. Clinically, prevention and management should be integrated into routine care and anchored in sustained, steroid-sparing disease control, combined with guideline-based in-hospital thromboprophylaxis and standard cardiovascular prevention. Decisions regarding anticoagulant therapy after VTEs should follow established principles while recognizing that recurrence prevention depends not only on anticoagulant choice but also on minimizing repeated inflammatory and treatment-related risk exposures. Cardiovascular risk assessment and optimization of modifiable factors should be considered before therapy escalation or treatment switching. Future advances will likely come from more personalized risk assessment across dynamic high-risk windows and from adjunctive, mechanism-informed strategies targeting key nodes of the gut-vascular interface and immunothrombosis.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41752670/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41752670')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41752670" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ From Inflammation to Thrombosis: The Prothrombotic State and Cardiovascular Risk in Inflammatory Bowel Disease.\nğŸ¥ Medicina (Kaunas, Lithuania)\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41752670/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Healthcare (Basel, Switzerland)</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Impact of Ostomy on Quality of Life in Patients with Colorectal Cancer: A Systematic Review and Meta-Analysis.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br></div>
            <div class="abs"></div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41753958/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41753958')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41753958" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Impact of Ostomy on Quality of Life in Patients with Colorectal Cancer: A Systematic Review and Meta-Analysis.\nğŸ¥ Healthcare (Basel, Switzerland)\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41753958/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Frontiers in oncology</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Clinical trials of bispecific antibody therapy for colorectal cancer: advanced and next steps.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>The clinical research and development activities of BsAbs in the field of CRC treatment are becoming increasingly active and mature. Currently, the focus is on establishing a safety profile. Dual-target blocking based on PD-1 and strategies targeting EGFR/cMET are the current main research and development directions. In contrast to resource-intensive CAR-T or payload-driven ADCs, BsAbs provide a ready-to-use therapeutic format that simultaneously engages two antigens, offering distinct practical and mechanistic benefits. In the future, it is necessary to further optimize the design of BsAbs, explore combination therapies and identify predictive biomarkers to promote its clinical transformation and improve the prognosis of CRC patients.</div>
            <div class="abs">Colorectal cancer (CRC) is a malignant tumor with a high incidence and mortality rate worldwide. The existing treatment methods have limitations in terms of efficacy or applicable population. Bispecific antibodies (BsAbs) can simultaneously target two different antigens and are expected to overcome tumor immune escape, providing a new strategy for the treatment of CRC.<br><br>This study systematically retrieved clinical trial registration platforms such as Trialtrove and ClinicalTrials.gov up to July and November 2025, and collected trial data on the treatment of CRC with BsAbs. Descriptive analyses were conducted on key indicators such as the stage distribution, primary endpoints, funding types, global distribution, and target combinations of the trials by establishing clear inclusion and exclusion criteria.<br><br>A total of 192 clinical trials were included. Since 2018, the number of related trials has significantly increased, and the trial phase has shifted from mainly Phase I in the early stage to a substantial growth in Phase II and Phase III trials after 2023-2024. The primary endpoints of the trial were highly concentrated on safety assessment (such as safety/tolerability, adverse events). The industrial sector is the main funder (68.3%), and the number of trials conducted in China (n=125) ranks first in the world. The target combinations are most commonly PD-1/CTLA-4 and PD-1/VEGF, and studies on novel combinations such as EGFR/cMET are also on the rise. Efficacy data from key trials (e.g., Cadonilimab, Amivantamab) demonstrate encouraging response rates in both locally advanced and metastatic settings, particularly in MSS/pMMR populations.<br><br>The clinical research and development activities of BsAbs in the field of CRC treatment are becoming increasingly active and mature. Currently, the focus is on establishing a safety profile. Dual-target blocking based on PD-1 and strategies targeting EGFR/cMET are the current main research and development directions. In contrast to resource-intensive CAR-T or payload-driven ADCs, BsAbs provide a ready-to-use therapeutic format that simultaneously engages two antigens, offering distinct practical and mechanistic benefits. In the future, it is necessary to further optimize the design of BsAbs, explore combination therapies and identify predictive biomarkers to promote its clinical transformation and improve the prognosis of CRC patients.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41756334/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41756334')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41756334" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Clinical trials of bispecific antibody therapy for colorectal cancer: advanced and next steps.\nğŸ¥ Frontiers in oncology\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41756334/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Frontiers in nutrition</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>There may be a differential mechanistic impact on colorectal cancer of lactose-containing foods between lactase persistent and lactase non-persistent populations.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>It is generally suggested that milk and milk products reduce the risk of colorectal cancer (CRC). While there is some controversy over specific sites affected throughout the colon and the benefits of specific dairy foods (DFs), there is a general consensus that calcium intake is the main mechanism of the cancer-reducing effects. This opinion may be sidelined by several other mechanisms. There is also a potentially important compensatory mechanism in populations with adult genetic lactase deficiency. The microbiome changes occur through a process of adaptation to continued lactose consumption. The bacterial blooms consist largely of </div>
            <div class="abs">It is generally suggested that milk and milk products reduce the risk of colorectal cancer (CRC). While there is some controversy over specific sites affected throughout the colon and the benefits of specific dairy foods (DFs), there is a general consensus that calcium intake is the main mechanism of the cancer-reducing effects. This opinion may be sidelined by several other mechanisms. There is also a potentially important compensatory mechanism in populations with adult genetic lactase deficiency. The microbiome changes occur through a process of adaptation to continued lactose consumption. The bacterial blooms consist largely of </div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41756623/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41756623')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41756623" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ There may be a differential mechanistic impact on colorectal cancer of lactose-containing foods between lactase persistent and lactase non-persistent populations.\nğŸ¥ Frontiers in nutrition\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41756623/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Diabetes, obesity & metabolism</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Evaluating the Impact of Putative Metformin Targets on Cancer Outcomes: A Drug-Target Mendelian Randomization Study.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>Metformin may prevent colorectal cancer via the AMPKÎ³1 (PRKAG1) target based on genetic evidence, supporting the evaluation of metformin use in colorectal cancer prevention using randomised controlled trials.</div>
            <div class="abs">Observational studies show metformin use associated with lower cancer risk, although experimental evidence is inconsistent. To provide genetic validation for repositioning of metformin in cancer prevention, we assessed genetically proxied effects of putative metformin targets on cancer outcomes using a drug-target Mendelian randomization (MR) design.<br><br>We identified genetic proxies of 11 metformin targets (PRKAA1, PRKAA2, PRKAB1, PRKAB2, PRKAG1, PRKAG2, PRKAG3, ETFDH, GPD1, SLC47A1 and ACACB) based on their associations with tissue-specific gene expression, overall/sex-specific HbA1c and type 2 diabetes. We then evaluated genetically proxied effects of these targets on five major cancers using MR. We also employed a conventional MR design to assess the relationship of HbA1c with cancer using the inverse variance method, with sensitivity analyses. Associations were corrected for multiple comparisons using false discovery rates.<br><br>We identified two genetic proxies of putative metformin targets (PRKAG1 and GPD1) as valid instrumental variables (F statistics >â€‰10). PRKAG1 was associated with a reduced risk of colorectal cancer (OR: 0.74 per mmol/mol reduction in overall HbA1c, 95% CI: 0.63-0.87; pâ€‰=â€‰0.001), with consistent findings in sex-specific analysis. This effect was unlikely mediated by HbA1c reduction, as indicated by conventional MR analyses (OR: 1.01 per mmol/mol, 95% CI: 0.99-1.02). No significant association was observed for GPD1 (OR: 1.00, 95% CI: 0.74-1.36; pâ€‰=â€‰0.98).<br><br>Metformin may prevent colorectal cancer via the AMPKÎ³1 (PRKAG1) target based on genetic evidence, supporting the evaluation of metformin use in colorectal cancer prevention using randomised controlled trials.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41755790/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41755790')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41755790" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Evaluating the Impact of Putative Metformin Targets on Cancer Outcomes: A Drug-Target Mendelian Randomization Study.\nğŸ¥ Diabetes, obesity & metabolism\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41755790/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Journal of clinical medicine</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Causal Impact of Hemoglobin Levels on Global Quality of Life in Patients with Cancer.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br></div>
            <div class="abs"></div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41753266/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41753266')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41753266" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Causal Impact of Hemoglobin Levels on Global Quality of Life in Patients with Cancer.\nğŸ¥ Journal of clinical medicine\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41753266/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Biomedicines</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>RPS6KA1 Remodels Fatty Acid Metabolism and Suppresses Malignant Progression in Colorectal Cancer.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br></div>
            <div class="abs"></div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41751273/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41751273')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41751273" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ RPS6KA1 Remodels Fatty Acid Metabolism and Suppresses Malignant Progression in Colorectal Cancer.\nğŸ¥ Biomedicines\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41751273/</textarea>
        </div>
    </details></div><div class='sec-group'><h3>ğŸº Liver Track</h3>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"><span class='badge if'>IF 29.4</span> <b>European journal of gastroenterology & hepatology</b>  ğŸ”¥</div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>The multifaceted role of secretome in hepatocellular carcinoma: a systematic review and meta-analysis.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ HCC surveillance ì¬ì„¤ì •</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>The secretome shows promise as a diagnostic and prognostic tool in HCC, with high sensitivity and specificity. However, further large-scale, standardized studies are needed to validate these findings and facilitate clinical translation.</div>
            <div class="abs">Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality, with a poor prognosis due to late diagnosis and limited treatment options. The secretome, encompassing proteins, metabolites, and extracellular vesicles secreted by cells, has emerged as a promising tool for early detection, risk stratification, and therapeutic targeting in HCC. Recent studies suggest that secretome-derived biomarkers improve diagnostic accuracy and predict survival outcomes. However, variability in methodologies and findings necessitates a comprehensive synthesis of evidence.<br><br>A systematic review and meta-analysis were conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. PubMed, EMBASE, and Scopus databases were searched on 2 May 2025 for studies evaluating the diagnostic and prognostic value of the secretome in HCC. Eligibility criteria included original research reporting sensitivity, specificity, or survival outcomes. Risk of bias was assessed using Quality Assessment of Diagnostic Accuracy Studies-2. Pooled estimates of sensitivity, specificity, and hazard ratios (HRs) were calculated using random-effects models, with heterogeneity assessed via IÂ² statistics.<br><br>Five studies met the inclusion criteria. The secretome demonstrated high diagnostic accuracy, with a pooled sensitivity of 95.9% [95% confidence intervals (CI): 40-100] and specificity of 89.6% (95% CI: 43.1-99). Moderate heterogeneity (IÂ² = 44%) was observed. For survival outcomes, the pooled HR was 2.37 (95% CI: 0.87-6.41), though statistical significance was not reached (Pâ€…=â€…0.07).<br><br>The secretome shows promise as a diagnostic and prognostic tool in HCC, with high sensitivity and specificity. However, further large-scale, standardized studies are needed to validate these findings and facilitate clinical translation.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41757612/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41757612')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41757612" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ The multifaceted role of secretome in hepatocellular carcinoma: a systematic review and meta-analysis.\nğŸ¥ European journal of gastroenterology & hepatology\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41757612/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"><span class='badge if'>IF 29.4</span> <b>Euroasian journal of hepato-gastroenterology</b>  ğŸ”¥</div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>A Silent Marker in Cirrhosis: The Toll of Vitamin D Deficiency on Age, Gender, and Quality of Life.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ USG 6ê°œì›” ê°„ê²©</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>Vitamin D deficiency is common in cirrhosis and contributes independently to worsening quality of life, particularly in women, older patients, and those with advanced disease. Incorporating vitamin D testing into routine management may provide an inexpensive, practical opportunity to improve patient outcomes, while further trials should clarify the therapeutic benefit of supplementation.</div>
            <div class="abs">Beyond the classic markers of liver failure, vitamin D deficiency has emerged as a silent driver of adverse outcomes in cirrhosis. By worsening survival prospects and daily functioning, it places an additional burden on patients. However, its prevalence, gender distribution, and impact on health-related quality of life (HRQoL) remain underexplored in South Asian populations.<br><br>We performed a cross-sectional analysis of 270 individuals with cirrhosis, confirmed by clinical and radiologic criteria, at a tertiary hospital in Faisalabad, Pakistan. Serum 25-hydroxyvitamin D [25(OH)D] concentrations were determined, with deficiency defined as < 20 ng/mL. Disease stage was classified by the Child-Pugh score, and HRQoL was measured using the SF-8 survey. Statistical evaluation included Chi-square, ANOVA, and multivariable linear regression.<br><br>Overall, 57.8% of participants were vitamin D deficient. The frequency rose with advancing cirrhosis (16.7% in class A, 51.9% in class B, 86.8% in class C; <br><br>Vitamin D deficiency is widespread among cirrhotic patients, with a higher burden in women and in advanced disease. Both deficiency and disease severity independently contribute to reduced quality of life. Incorporating vitamin D screening and supplementation into cirrhosis care may be beneficial, and randomized trials are warranted to assess clinical impact.<br><br>Vitamin D deficiency is common in cirrhosis and contributes independently to worsening quality of life, particularly in women, older patients, and those with advanced disease. Incorporating vitamin D testing into routine management may provide an inexpensive, practical opportunity to improve patient outcomes, while further trials should clarify the therapeutic benefit of supplementation.<br><br>Shafqat U, Rasool S, Azhar S, </div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41757145/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41757145')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41757145" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ A Silent Marker in Cirrhosis: The Toll of Vitamin D Deficiency on Age, Gender, and Quality of Life.\nğŸ¥ Euroasian journal of hepato-gastroenterology\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41757145/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Frontiers in genetics</b>  ğŸ”¥</div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>The impact of circulating tumor DNA on the prognosis of liver cancer and its predictive value: a meta analysis.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ HCC surveillance ì¬ì„¤ì •</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>ctDNA is associated with adverse prognosis in HCC and may offer moderate predictive accuracy for recurrence. Standardized protocols for sampling and analysis are required to facilitate broader clinical translation.</div>
            <div class="abs">ctDNA is a promising biomarker in oncology. However, its prognostic and predictive value in HCC remains underexplored. This meta-analysis aims to evaluate the prognostic impact of ctDNA in HCC and its predictive value for recurrence.<br><br>A systematic review and meta-analysis were performed following PRISMA guidelines. PubMed, Embase, Web of Science, and CNKI were searched up to 1 June 2025, for studies assessing ctDNA in HCC patients with reported survival outcomes or predictive accuracy. Studies reporting hazard ratios for overall or disease-free survival, or AUCs for prediction, were included. Two reviewers independently screened studies and assessed quality using the Newcastle-Ottawa Scale (NOS). Meta-analyses used random- or fixed-effects models depending on heterogeneity, with sensitivity analyses performed to assess robustness.<br><br>A total of 219 records were screened from PubMed, Embase, Web of Science, and CNKI, and 8 studies comprising 1,907 patients were included. ctDNA positivity was significantly associated with poorer OS, with a pooled HR of 2.34 (95% CI 1.96-2.78; p < 0.0001). Moderate heterogeneity was observed (I<br><br>ctDNA is associated with adverse prognosis in HCC and may offer moderate predictive accuracy for recurrence. Standardized protocols for sampling and analysis are required to facilitate broader clinical translation.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41757268/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41757268')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41757268" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ The impact of circulating tumor DNA on the prognosis of liver cancer and its predictive value: a meta analysis.\nğŸ¥ Frontiers in genetics\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41757268/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"><span class='badge if'>IF 29.4</span> <b>European journal of gastroenterology & hepatology</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Type 2 diabetes mellitus and liver diseases: a phenome-wide Mendelian randomization atlas and genome-wide genetic correlation study.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>Our research has comprehensively revealed the clear causal relationship between T2DM and specific liver diseases, emphasizing the importance of preventing such diseases in patients with T2DM. These findings not only confirm and expand the existing knowledge framework regarding the relationship between T2DM and liver diseases but also provide new insights for clinical practice and future research directions.</div>
            <div class="abs">The causal relationship between type 2 diabetes mellitus (T2DM) and the various liver disease phenotypes remains uncertain.<br><br>Our study provides a comprehensive causal atlas by assessing the causal roles of T2DM across 12 major liver conditions using summary data from genome-wide association studies.<br><br>Our study indicated significant genetic correlations between T2DM and five types of liver diseases, with suggestive levels for three additional types. Furthermore, we found evidence of the causal effects of T2DM on seven types of liver diseases. Specifically, T2DM showed significant causality with metabolic dysfunction-associated steatotic liver disease [odds ratio (OR) = 1.49, 95% confidence interval (CI): 1.37-1.62, P = 2.55â€‰Ã—â€‰10-21], cirrhosis of liver (OR = 1.18, 95% CI: 1.05-1.33, P = 3.98â€‰Ã—â€‰10-3), chronic hepatitis (OR = 1.20, 95% CI: 1.06-1.37, P = 3.72â€‰Ã—â€‰10-3), and hepatocellular carcinoma (OR = 1.31, 95% CI: 1.10-1.56, P = 3.02â€‰Ã—â€‰10-3). In addition, suggestive causality was found between T2DM and nonalcoholic steatohepatitis (OR = 1.45, 95% CI: 1.08-1.95, P = 0.012), fibrosis of liver (OR = 1.47, 95% CI: 1.08-2.00, P = 0.015), and malignant liver neoplasm (OR = 1.21, 95% CI: 1.04-1.42, P = 0.013).<br><br>Our research has comprehensively revealed the clear causal relationship between T2DM and specific liver diseases, emphasizing the importance of preventing such diseases in patients with T2DM. These findings not only confirm and expand the existing knowledge framework regarding the relationship between T2DM and liver diseases but also provide new insights for clinical practice and future research directions.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41757613/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41757613')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41757613" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Type 2 diabetes mellitus and liver diseases: a phenome-wide Mendelian randomization atlas and genome-wide genetic correlation study.\nğŸ¥ European journal of gastroenterology & hepatology\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41757613/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>The American journal of managed care</b>  ğŸ”¥</div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Quality of life: the pending outcome in idiopathic pulmonary fibrosis.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>Recent real-world evidence on idiopathic pulmonary fibrosis (IPF) has provided important insights into survival and disease progression; however, critical patient-centered outcomes remain insufficiently addressed. The articleÂ "Real-World Data on the Course of Idiopathic Pulmonary Fibrosis," published in an October 2024 supplement to The American Journal of Managed Care , highlights this limitation by focusing predominantly on objective clinical parameters while lacking systematic evaluation of health-related quality of life (HRQOL). This gap is particularly relevant given limited evidence on how antifibrotic therapies affect symptoms, pulmonary function, and psychosocial well-being beyond radiologic progression. QOL is especially relevant in resource-limited settings, where demonstrating benefits in symptom control and functional status may influence therapeutic decisions, coverage policies, and resource allocation. Although international clinical practice guidelines, including those of the American Thoracic Society and the European Respiratory Society, recognize QOL as a key domain in IPF management, they also acknowledge the paucity of evidence addressing psychosocial and functional outcomes. Notably, major clinical trials such as INPULSIS and ASCEND, while demonstrating efficacy in slowing forced vital capacity decline, did not incorporate HRQOL as a primary outcome. Recent guideline updates propose a conceptual framework integrating validated measures of symptoms, pulmonary function, and psychosocial impact. However, these dimensions have not yet been systematically embedded in clinical research. Reanalysis of existing data and future studies using this framework are warranted. AÂ comprehensive evaluation of quality of life is therefore a clinical and ethical imperative for advancing patient-centered and holistic care in IPF.</div>
            <div class="abs">Recent real-world evidence on idiopathic pulmonary fibrosis (IPF) has provided important insights into survival and disease progression; however, critical patient-centered outcomes remain insufficiently addressed. The articleÂ "Real-World Data on the Course of Idiopathic Pulmonary Fibrosis," published in an October 2024 supplement to The American Journal of Managed Care , highlights this limitation by focusing predominantly on objective clinical parameters while lacking systematic evaluation of health-related quality of life (HRQOL). This gap is particularly relevant given limited evidence on how antifibrotic therapies affect symptoms, pulmonary function, and psychosocial well-being beyond radiologic progression. QOL is especially relevant in resource-limited settings, where demonstrating benefits in symptom control and functional status may influence therapeutic decisions, coverage policies, and resource allocation. Although international clinical practice guidelines, including those of the American Thoracic Society and the European Respiratory Society, recognize QOL as a key domain in IPF management, they also acknowledge the paucity of evidence addressing psychosocial and functional outcomes. Notably, major clinical trials such as INPULSIS and ASCEND, while demonstrating efficacy in slowing forced vital capacity decline, did not incorporate HRQOL as a primary outcome. Recent guideline updates propose a conceptual framework integrating validated measures of symptoms, pulmonary function, and psychosocial impact. However, these dimensions have not yet been systematically embedded in clinical research. Reanalysis of existing data and future studies using this framework are warranted. AÂ comprehensive evaluation of quality of life is therefore a clinical and ethical imperative for advancing patient-centered and holistic care in IPF.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41759200/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41759200')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41759200" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Quality of life: the pending outcome in idiopathic pulmonary fibrosis.\nğŸ¥ The American journal of managed care\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41759200/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Pediatric surgery international</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Hypoxia-conditioned umbilical cord mesenchymal stem cell secretome attenuates hepatic fibrosis in a bile duct ligation model of biliary atresia.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>Hypoxia-conditioned UC-MSC secretome improved hepatic function and mitigated fibrosis in the BDL model through suppression of profibrotic and inflammatory mediators. These findings support HU-UCMSC secretome as a safe, cell-free therapeutic candidate for biliary atresia and related pediatric cholestatic liver diseases.</div>
            <div class="abs">Biliary atresia (BA) is a progressive fibro-inflammatory cholangiopathy and the leading cause of neonatal cholestasis and pediatric liver transplantation. Mesenchymal stem cell (MSC)-derived secretome has emerged as promising acellular alternative to cell therapy. This study evaluated the potential of hypoxia-conditioned umbilical cord MSC (HU-UCMSC) secretome in rat model of biliary fibrosis induced by bile duct ligation (BDL).<br><br>Twenty-four male Sprague-Dawley rats were randomized into six groups: Sham, BDL, BDLâ€‰+â€‰vehicle, and BDL treated with HU-UCMSC secretome at doses of 100, 200, and 400 Î¼L. Serum biochemical markers and hepatic gene expression were analyzed using photometry and RT-qPCR. Histopathology and fibrosis fraction area were evaluated by Sirius Red staining.<br><br>HU-UCMSC secretome produced dose-dependent hepatoprotection, significantly reducing SGOT, SGPT, and total bilirubin levels compared with untreated BDL rats. Histologically, collagen deposition and fibrosis fraction area were markedly reduced. Gene expression analysis showed significant downregulation of PDGF, Î±-SMA, and TNF-Î±, with context-dependent modulation of TGF-Î² and VEGF.<br><br>Hypoxia-conditioned UC-MSC secretome improved hepatic function and mitigated fibrosis in the BDL model through suppression of profibrotic and inflammatory mediators. These findings support HU-UCMSC secretome as a safe, cell-free therapeutic candidate for biliary atresia and related pediatric cholestatic liver diseases.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41758387/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41758387')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41758387" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Hypoxia-conditioned umbilical cord mesenchymal stem cell secretome attenuates hepatic fibrosis in a bile duct ligation model of biliary atresia.\nğŸ¥ Pediatric surgery international\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41758387/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Veterinary medicine and science</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Economic Impact and Disease Insights: Understanding Organ Condemnation in Cattle Slaughtered at Bahir Dar Abattoir.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>The current study implies that there was considerable edible offal condemnation resulting in significant economic loss. This instigates that it is crucial to adopt efficient animal management practices, conduct regular health assessments of animals and provide educational programmes for animal owners on disease prevention strategies like deworming to reduce the incidence of organ condemnation and its financial impacts in the region.</div>
            <div class="abs">Abattoir surveillance is the font of valuable information on the incidence and epidemiology of animal disease, having both public and animal health importance. A cross-sectional study followed by simple random sampling was conducted from December 2021 to May 2022 to identify the major causes of edible offal condemnation and to estimate the financial losses attributed to edible offal condemnation in cattle slaughtered at Bahir Dar municipal abattoir, northwestern Ethiopia, using antemortem and post-mortem examination.<br><br>Out of 334 cattle investigated, 3.6% (12/334) cattle showed detectable abnormalities including diarrhoea in 0.6% (2/12), lameness in 0.9% (3/12) and tick infestation in 1.2% (4/12), and nasal discharge in 0.9% (3/12) in cattle during an antemortem examination. However, in post-mortem examination, 22.16% (74/334) of cattle revealed lesions in visceral organs including the liver (14.6%), lung (9.9%), kidney (1.8%), heart (2.4%) and tongue (0.9%). The major causes that were identified in the current study include calcification, fasciolosis, hydatid cyst, cirrhosis, abscess, pneumonia, haemorrhage, emphysema, congestion, pericarditis, Cysticercus bovis, nephritis and renal calculi. Among the putative risk factors, only body condition was shown to have statistically significant variation (pÂ <Â 0.05) with the prevalence of major causes of organ condemnation upon post-mortem examination. The overall financial losses incurred due to organ condemnation were estimated to be $475.19, with an annual loss of $15,447.85.<br><br>The current study implies that there was considerable edible offal condemnation resulting in significant economic loss. This instigates that it is crucial to adopt efficient animal management practices, conduct regular health assessments of animals and provide educational programmes for animal owners on disease prevention strategies like deworming to reduce the incidence of organ condemnation and its financial impacts in the region.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41758074/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41758074')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41758074" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Economic Impact and Disease Insights: Understanding Organ Condemnation in Cattle Slaughtered at Bahir Dar Abattoir.\nğŸ¥ Veterinary medicine and science\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41758074/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Microbiology spectrum</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>The regional landscape of the human colon culturome in health and cystic fibrosis.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>This pilot study of a small cohort represents the first culturome analysis of the cystic fibrosis colon. Our preliminary findings demonstrate that cystic fibrosis (CF)-associated gut dysbiosis is spatially specific, with mucosal bacterial communities showing pronounced alterations while luminal communities show comparatively subtle phylum-specific shifts. This spatial specificity suggests the mucosal microenvironment as a potential therapeutic target and indicates that interventions focused solely on luminal bacteria may be insufficient. The promising predictive accuracy of culturome-based machine learning models in this small cohort suggests these viable bacterial signatures could serve as biomarkers for CF management pending larger validation studies. Additionally, our initial observations of CFTR modulator effects on gut microbial communities provide insight for future studies optimizing combination therapies.</div>
            <div class="abs">Cystic fibrosis (CF) alters gut physiology, yet its impact on microbial communities across colonic regions (ascending, transverse, descending colon) and microhabitats (lumen, mucosa) remains incompletely understood. Here, we applied culturomics to characterize gut microbiota in a small cohort of 32 individuals (22 non-CF, 10 CF). Persons with CF (pwCF) exhibited significantly higher viable bacterial loads than non-CF individuals, particularly in mucosal samples. Anaerobes predominated overall, with relative enrichment of aerobes in the mucosa of pwCF. Alpha diversity was reduced in mucosal samples and aerobic cultures for pwCF, whereas beta diversity was influenced by all the tested variables except the colonic region. Phylum-level analyses revealed enrichment of Proteobacteria and depletion of Actinobacteria, Bacteroidota, and Firmicutes in samples from pwCF, consistent with stool analysis. Random forest models identified selected oral-associated microbes as key predictive taxa and accurately classified polyp status within this cohort. Whole-genome sequencing of <br><br>This pilot study of a small cohort represents the first culturome analysis of the cystic fibrosis colon. Our preliminary findings demonstrate that cystic fibrosis (CF)-associated gut dysbiosis is spatially specific, with mucosal bacterial communities showing pronounced alterations while luminal communities show comparatively subtle phylum-specific shifts. This spatial specificity suggests the mucosal microenvironment as a potential therapeutic target and indicates that interventions focused solely on luminal bacteria may be insufficient. The promising predictive accuracy of culturome-based machine learning models in this small cohort suggests these viable bacterial signatures could serve as biomarkers for CF management pending larger validation studies. Additionally, our initial observations of CFTR modulator effects on gut microbial communities provide insight for future studies optimizing combination therapies.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41757945/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41757945')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41757945" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ The regional landscape of the human colon culturome in health and cystic fibrosis.\nğŸ¥ Microbiology spectrum\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41757945/</textarea>
        </div>
    </details></div><div class='sec-group'><h3>ğŸ§¬ Biliary/Pancreas</h3>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace</b> <span class='badge rct'>RCT</span></div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Efficacy and safety of antisense oligonucleotide therapies targeting APoC-III in patients with severe hypertriglyceridemia: a meta-analysis of randomized controlled trials.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>Hypertriglyceridemia (HTG) increases cardiovascular and pancreatitis risk. Antisense oligonucleotide (ASO) therapies like volanesorsen and olezarsen target ApoC-III mRNA to reduce ApoC-III, enhancing lipoprotein lipase activity and lowering triglycerides (TGs). This meta-analysis evaluates the efficacy and safety of these ASOs in severe HTG. A systematic review (PROSPERO: CRD42024577110) was conducted following PRISMA, sourcing studies from PubMed, Scopus, Cochrane CENTRAL, and ClinicalTrials.gov until July 2024. Randomized controlled trials (RCTs) involving severe HTG (â‰¥200 mg/dL) treated with volanesorsen or olezarsen vs. placebo were included. Data were synthesized using a random effects model in RevMan 5.4, and bias was assessed with the Cochrane tool. Of 31 identified articles, 9 RCTs (341 patients treated with ASOs, 209 controls) were included. ASOs significantly reduced TG levels [mean difference (MD): -53.72; 95% confidence interval (CI): -77.04 to -30.40; p<0.00001]. Reductions were also seen in very low-density lipoprotein cholesterol (MD: -55.76; p<0.00001), ApoC-III (MD: -74.78; p<0.00001), and APOB48 (MD: -69.45; p<0.00001). Olezarsen uniquely reduced APOB (MD: -15.60; p<0.00001). Non-high-density lipoprotein cholesterol (HDL-C) decreased (MD: -23.25; p<0.00001), while HDL-C increased (MD: +42.14; p<0.00001). Volanesorsen was linked to higher low-density lipoprotein-cholesterol (MD: +62.74; p=0.004). For safety, local injection reactions, thrombocytopenia, and nausea were more common with volanesorsen. Acute pancreatitis occurred only in the placebo group (relative risk: 0.15; p=0.0004), indicating ASO protection. This meta-analysis confirms that ASOs effectively lower TGs and improve lipid profiles in severe HTG.</div>
            <div class="abs">Hypertriglyceridemia (HTG) increases cardiovascular and pancreatitis risk. Antisense oligonucleotide (ASO) therapies like volanesorsen and olezarsen target ApoC-III mRNA to reduce ApoC-III, enhancing lipoprotein lipase activity and lowering triglycerides (TGs). This meta-analysis evaluates the efficacy and safety of these ASOs in severe HTG. A systematic review (PROSPERO: CRD42024577110) was conducted following PRISMA, sourcing studies from PubMed, Scopus, Cochrane CENTRAL, and ClinicalTrials.gov until July 2024. Randomized controlled trials (RCTs) involving severe HTG (â‰¥200 mg/dL) treated with volanesorsen or olezarsen vs. placebo were included. Data were synthesized using a random effects model in RevMan 5.4, and bias was assessed with the Cochrane tool. Of 31 identified articles, 9 RCTs (341 patients treated with ASOs, 209 controls) were included. ASOs significantly reduced TG levels [mean difference (MD): -53.72; 95% confidence interval (CI): -77.04 to -30.40; p<0.00001]. Reductions were also seen in very low-density lipoprotein cholesterol (MD: -55.76; p<0.00001), ApoC-III (MD: -74.78; p<0.00001), and APOB48 (MD: -69.45; p<0.00001). Olezarsen uniquely reduced APOB (MD: -15.60; p<0.00001). Non-high-density lipoprotein cholesterol (HDL-C) decreased (MD: -23.25; p<0.00001), while HDL-C increased (MD: +42.14; p<0.00001). Volanesorsen was linked to higher low-density lipoprotein-cholesterol (MD: +62.74; p=0.004). For safety, local injection reactions, thrombocytopenia, and nausea were more common with volanesorsen. Acute pancreatitis occurred only in the placebo group (relative risk: 0.15; p=0.0004), indicating ASO protection. This meta-analysis confirms that ASOs effectively lower TGs and improve lipid profiles in severe HTG.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41755797/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41755797')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41755797" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Efficacy and safety of antisense oligonucleotide therapies targeting APoC-III in patients with severe hypertriglyceridemia: a meta-analysis of randomized controlled trials.\nğŸ¥ Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41755797/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Frontiers in pharmacology</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Reassessing cancer risk with GLP-1 receptor agonists: a comprehensive meta-analysis of gastrointestinal malignancies.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>This meta-analysis of RCTs provides reassuring evidence that GLP-1 receptor agonists were not associated with an increased risk of gastrointestinal cancers, with signals suggesting a possible reduction in colorectal and liver cancer incidence that should be interpreted cautiously. These results support the continued safe use of GLP-1 RAs in T2DM and obesity, although longer trials with cancer-specific endpoints are warranted. This review was registered in Open Science Framework https://osf.io/3rv6d/overview.</div>
            <div class="abs">Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely prescribed for type 2 diabetes mellitus (T2DM) and obesity. While their metabolic benefits are established, concerns persist about a possible link with gastrointestinal (GI) cancers. This study aimed to clarify the association between GLP-1 RA use and GI cancer risk.<br><br>A systematic search of PubMed, Embase, and Scopus till August 2024 identified randomized controlled trials (RCTs) reporting GI cancer outcomes. Ninety-three RCTs with 1.85 million participants were included. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using a random-effects model, with subgroup analyses by cancer type and exposure duration.<br><br>GLP-1 RA use was not associated with an increased overall risk of GI cancers (HR 0.81: 95% CI: 0.68-0.96). Subgroup analyses indicated reduced risks of colorectal cancer (HR 0.81: 95% CI: 0.68-0.96) and liver cancer (HR: 0.74; 95% CI: 0.62-0.88). Pancreatic cancer risk was not significantly elevated (HR: 0.78; 95% CI: 0.61-0.95). Findings were consistent across sensitivity analyses.<br><br>This meta-analysis of RCTs provides reassuring evidence that GLP-1 receptor agonists were not associated with an increased risk of gastrointestinal cancers, with signals suggesting a possible reduction in colorectal and liver cancer incidence that should be interpreted cautiously. These results support the continued safe use of GLP-1 RAs in T2DM and obesity, although longer trials with cancer-specific endpoints are warranted. This review was registered in Open Science Framework https://osf.io/3rv6d/overview.<br><br>https://osf.io/3rv6d/overview.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41743116/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41743116')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41743116" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Reassessing cancer risk with GLP-1 receptor agonists: a comprehensive meta-analysis of gastrointestinal malignancies.\nğŸ¥ Frontiers in pharmacology\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41743116/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Foods (Basel, Switzerland)</b> <span class='badge rct'>RCT</span></div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Impact of Acute (Poly)Phenol-Rich Sugarcane Extract Consumption on Postprandial Glycemic Response in Healthy Adults: A Randomized Crossover Study.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br></div>
            <div class="abs"></div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41750823/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41750823')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41750823" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Impact of Acute (Poly)Phenol-Rich Sugarcane Extract Consumption on Postprandial Glycemic Response in Healthy Adults: A Randomized Crossover Study.\nğŸ¥ Foods (Basel, Switzerland)\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41750823/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>International journal of molecular sciences</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Spexin as a Novel Biomarker for Predicting Disease Severity and Mortality in Acute Pancreatitis.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>This study aimed to investigate the diagnostic and prognostic value of serum spexin levels in patients with acute pancreatitis (AP) and to assess their association with disease severity and mortality. A total of 34 AP patients and 34 healthy individuals were included in the study. AP patients were classified into three groups: mild, moderately severe, and severe (SAP). Serum spexin levels were measured using ELISA, and biochemical parameters, inflammatory indices, and clinical scores were compared. Univariate logistic regression analysis was performed to evaluate factors associated with AP severity and mortality, and ROC analysis was used to assess the diagnostic performance. The median spexin level in AP patients was significantly higher than in healthy controls (</div>
            <div class="abs">This study aimed to investigate the diagnostic and prognostic value of serum spexin levels in patients with acute pancreatitis (AP) and to assess their association with disease severity and mortality. A total of 34 AP patients and 34 healthy individuals were included in the study. AP patients were classified into three groups: mild, moderately severe, and severe (SAP). Serum spexin levels were measured using ELISA, and biochemical parameters, inflammatory indices, and clinical scores were compared. Univariate logistic regression analysis was performed to evaluate factors associated with AP severity and mortality, and ROC analysis was used to assess the diagnostic performance. The median spexin level in AP patients was significantly higher than in healthy controls (</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41751978/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41751978')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41751978" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Spexin as a Novel Biomarker for Predicting Disease Severity and Mortality in Acute Pancreatitis.\nğŸ¥ International journal of molecular sciences\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41751978/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Cancer research communications</b>  ğŸ”¥</div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Lenvatinib Plus Pembrolizumab for Patients With Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results From the Phase 2 LEAP-005 Study.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>Lenvatinib plus pembrolizumab demonstrated modest antitumor activity and a manageable safety profile in previously treated, advanced gastric cancer, BTC, and PDAC.</div>
            <div class="abs">Patients with gastric cancer, biliary tract cancer (BTC), and pancreatic ductal adenocarcinoma (PDAC) have poor survival outcomes and limited second- or later-line treatment options. Certain drugs targeting vascular endothelial growth factor (VEGF) or programmed cell death protein 1 (PD-1) signaling pathways are currently used in these cancers in specific circumstances; however, there remains a need for novel treatment combinations. LEAP-005 is a multicohort, open-label, phase 2 study that evaluated lenvatinib (multitargeted inhibitor of tyrosine kinases, including VEGF) plus pembrolizumab (antiâ€’PD-1 monoclonal antibody) in select previously treated solid tumors.<br><br>Participants with previously treated, advanced gastric cancer, BTC, and PDAC were enrolled in cohorts C, F, and G of LEAP-005, respectively, and received lenvatinib 20 mg/day orally plus pembrolizumab 200 mg intravenously every 3 weeks. Primary endpoints were objective response rate (ORR) and safety.<br><br>Of 99, 102, and 103 total participants enrolled in cohorts C, F, and G, respectively, median times from first dose of study treatment to data cutoff (February 6, 2023) were 23.7, 24.2, and 19.5 months. ORRs (95% CI) by blinded independent central review were 15.2% (8.7%â€’23.8%) in cohort C, 17.6% (10.8%â€’26.4%) in cohort F, and 7.8% (3.4%â€’14.7%) in cohort G. Grade 3â€’5 treatment-related adverse events occurred in 54.5% of participants in cohort C, and grade 3â€’4 (no grade 5) occurred in 60.8% and 59.2% of participants in cohorts F and G, respectively.<br><br>Lenvatinib plus pembrolizumab demonstrated modest antitumor activity and a manageable safety profile in previously treated, advanced gastric cancer, BTC, and PDAC.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41747221/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41747221')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41747221" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Lenvatinib Plus Pembrolizumab for Patients With Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results From the Phase 2 LEAP-005 Study.\nğŸ¥ Cancer research communications\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41747221/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Life (Basel, Switzerland)</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Genetic Susceptibility to </div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br></div>
            <div class="abs"></div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41752920/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41752920')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41752920" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Genetic Susceptibility to \nğŸ¥ Life (Basel, Switzerland)\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41752920/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Neurobiology of disease</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Unveiling the hidden genetic conundrum linking pulmonary diseases and neuropsychiatric disorders: Novel insights from advanced omics-based analyses of the lung-brain axis.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>These findings indicate that pleiotropic genetic factors connecting pulmonary and neuropsychiatric diseases are widely distributed throughout the genome. This provides robust evidence for a shared genetic basis underlying the lung-brain axis and has important implications for the potential for developing targeted intervention and treatment that simultaneously address both diseases types.</div>
            <div class="abs">This study seeks to elucidate the shared genetic underpinnings between these pulmonary diseases and neuropsychiatric disorders, focusing on common genomic loci, implicated genes, and biochemical pathways.<br><br>This study is a genome-wide pleiotropic association study that utilized genome-wide association summary statistics from publicly available data sources. Diverse bioinformatics and statistical genetics strategies were applied to sequentially investigate the pleiotropic associations from single-nucleotide variant (SNV), gene-level data, and biological pathways, with the aim to better understand the shared genetic etiology between 3 pulmonary diseases and 7 neuropsychiatric disorders.<br><br>Significant genetic correlations and overlaps were observed among 20 of the 21 trait pairs. Pleiotropic analysis, using a composite null hypothesis, identified 3962 potentially pleiotropic SNVs across 20 trait pairs, along with 31 pleiotropic loci and 3 colocalized loci. Gene-based analysis revealed 103 unique candidate pleiotropic genes, which were notably enriched in phenotypes and tissues associated with the lung-brain axis (LBA). Pathway enrichment analysis highlighted key biological processes related to cell adhesion, synaptic structure and function, and immune cell differentiation. Several pleiotropic loci were also found to share causal variants with lung-related phenotypes. Mendelian randomization analysis suggested vertical pleiotropy across 8 trait pairs.<br><br>These findings indicate that pleiotropic genetic factors connecting pulmonary and neuropsychiatric diseases are widely distributed throughout the genome. This provides robust evidence for a shared genetic basis underlying the lung-brain axis and has important implications for the potential for developing targeted intervention and treatment that simultaneously address both diseases types.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41747966/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41747966')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41747966" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Unveiling the hidden genetic conundrum linking pulmonary diseases and neuropsychiatric disorders: Novel insights from advanced omics-based analyses of the lung-brain axis.\nğŸ¥ Neurobiology of disease\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41747966/</textarea>
        </div>
    </details></div>
    </div>

    <footer style="text-align:center; padding:15px; color:#95a5a6; font-size:0.75rem;">ğŸš€ Project: MedProductive Clinical AI</footer>

    <script>
        function toggleF() {
            const btn = document.getElementById('fBtn'); btn.classList.toggle('active');
            const isF = btn.classList.contains('active');
            btn.style.background = isF ? 'var(--success)' : '#fff';
            btn.style.color = isF ? '#fff' : 'var(--success)';
            document.querySelectorAll('.paper-item').forEach(p => {
                p.style.display = isF ? (p.querySelector('.badge-guideline') ? 'block' : 'none') : 'block';
            });
        }
        function copyShare(id) {
            const el = document.getElementById('s_'+id);
            navigator.clipboard.writeText(el.value.replace(/\\n/g, '\n')).then(() => alert("âœ… ë³µì‚¬ ì™„ë£Œ!"));
        }
        
        // ë„ë„› ì°¨íŠ¸ë§Œ ë Œë”ë§
        new Chart(document.getElementById('c2'), { 
            type:'doughnut', 
            data:{ labels:["GI", "Liver", "Biliary/Pancreas"], datasets:[{data:[7, 8, 7], backgroundColor:['#e74c3c','#f1c40f','#2ecc71']}] }, 
            options: { 
                responsive: true, 
                maintainAspectRatio: false, 
                plugins: { 
                    legend: { position: 'right', labels: { font: { size: 10 } } } 
                } 
            } 
        });
    </script>
</body>
</html>
